期刊文献+

蔗糖铁及右旋糖酐铁对儿科静脉营养液中脂肪乳剂稳定性的影响 被引量:6

Effects of iron dextran or iron sucrose on the stability of fat emulsion in total nutrient admixtures for pediatric patients
原文传递
导出
摘要 目的 分析静脉营养液中分别加入两种不同铁剂(蔗糖铁及右旋糖酐铁)后对脂肪乳剂稳定性的影响。方法 按静脉营养配制操作规范加入两种不同剂量铁剂(分别为蔗糖铁及右旋糖酐铁)的静脉营养液各10袋,肉眼观察含不同当量铁剂(0.25、0.50、0.75和1.00 mg )的静脉营养液在室温(25 ℃)悬挂静置3 d,扫描电镜观察3 d内的脂肪颗粒平均大小、直径>0.5 μm百分比、营养混合液的pH值及渗透浓度。结果 含不同铁剂的营养液在不同时间点的脂肪颗粒大小差异无统计学性意义(F=0.32,P=0.7836;F=1.73,P=0.1321)。72 h内各组脂肪乳颗粒平均大小均<0.5 μm,并且均未见到直径>5 μm的脂肪颗粒,含不同浓度铁的TNA在不同时间点间脂肪颗粒>0.5 μm的百分比、pH值及渗透压差异均无统计学意义 (百分比:F=1.47,P=0.3467;F=1.04,P=0.4758。pH值:F=0.63,P=0.5942;F=0.46,P=0.6825。渗透压:F=1.37,P=0.3648;F=0.65,P=0.6023)。结论 浓度小于1%蔗糖铁及右旋糖酐铁分别加入儿科静脉营养液是稳定的。 Objective To evaluate the effects of iron dextran or iron sucrose on the stability of fat emulsion in total nutrient admixture (TNA) in pediatric settings. Methods TNA with different intravenous doses of iron sucrose or iron dextran (0.25, 0.5, 0.75, or 1.00 mg) were prepared, and each dose was prepared 10 bags. The TNAs were stored at 25 ℃ for 3 days, and the stability of fat emulsion was observed by electron scanning microscopy. Meanwhile, the pH and osmolality were also measured. Results The particle sizes of fat emulsions in TNA with different concentrations of iron sucrose or iron dextran at different time points were not significantly different (F=0.32,P=0.7836;F=1.73,P=0.1321, respectively). The mean particle size of the fat emulsion in each group was 〈0.5 μm within 72 hours. For TNA containing different concentrations of iron, the percentage of particles〉 0.5 μm, pH, and osmotic pressure showed no significant difference at different time points (percentage: F=1.47,P=0.3467;F=1.04,P=0.4758. pH: F=0.63,P=0.5942;F=0.46,P=0.6825.osmotic pressure:F=1.37,P=0.3648;F=0.65,P=0.6023). ConclusionThe TNA addeded with iron sucrose or iron dextran with an concentrations of 〈1% is stable.
出处 《中华临床营养杂志》 CAS CSCD 2013年第4期213-217,共5页 Chinese Journal of Clinical Nutrition
基金 昆山市社会发展科技计划项目(KS1124)
关键词 静脉营养液 蔗糖铁 右旋糖酐铁 脂肪乳剂 稳定性 Total nutrient admixture Iron sucrose Iron dextran Fat emulsion Stability
  • 相关文献

参考文献13

  • 1Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations [ J ]. Nephrol Dial Trans- plant, 2004, 19 (6) : 1571-1575.
  • 2Tu YH, Knox NL, Biringer JM, et al. Compatibility of iron dex- tran with total nutrient admixtures [ J ]. Am J Hosp Pharm,1992, 49 (9) : 2233-2235.
  • 3Mayhew SL, Quick MW. Compatibility of iron dextran with neo- natral parenteral nutrient solutions [ J ]. Am J Health Syst Pharm, 1997, 54 (5): 570-571.
  • 4乔林霞,汤庆娅,费延文,王莹.儿科用静脉营养液中加入蔗糖铁对脂肪乳剂稳定性的影响[J].中华临床营养杂志,2010,18(2):111-114. 被引量:5
  • 5乔林霞,朱文英,王华.静脉补充铁剂对早产儿铁储存的影响[J].苏州大学学报(医学版),2012,32(4):587-589. 被引量:3
  • 6Friel JK, Andrews WL, Hall MS, et al. Intravenous iron admin- istration to very-low-birth-weight newborns receiving total and partial parenteral nutrition [J]. JPEN J Parenter Enteral Nutr, 1995, 19 (2): 114-118.
  • 7Silverstein SB, Rodgers GM. Parenteral iron therapy options [J]. AmJHematol, 2004, 76 (1):74-78.
  • 8Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on ad- verse drug events associated with parenteral iron [ J ]. Nephrol Dial Transplant, 2006, 21 (2) : 378-382.
  • 9Sobotka L.临床营养基础[M].3版.上海:复旦大学出版社,2007.
  • 10Koletzko B, Goulet O, Hunt J, et al. Guidelines on paediatric parenteral nutrition [ J]. J Pediatr Gastroenterol Nutr, 2005, 41 (2) : S1-$87.

二级参考文献13

  • 1Dickson LB,Somani SM,Herrmann G,et al.Automated compounder for adding ingredients to parenteral nutrient base solutions[J].Am J Hosp Pharm,1993,50(4):678-682.
  • 2Fishwick JJ,Murphy CC,Riesenberg MC,et al.Weight-based accuracy of parenteral nutrient solutions prepared with an automated compounder[J].American Journal of Health-system Pharmacy,1997,54(6):678-679.
  • 3Driscoll DF.Clinical delivery of nutritional therapy:automated compounders and patient-specific feeding[J].Nutrition,1996,12(6):461-462.
  • 4Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin treated premature infants [ J]. Pediatrics,2001,107 ( 1 ) : 78 - 85.
  • 5Julia C. Adverse events associated with intravenous iron in- fusion (low-molecular-weight iron dextran and iron su- crose) :a systematic review [ J ]. Transfusion Alternatives in Transfusion Medicine, 2007,9( 1 ) : 8 - 36.
  • 6Friel JK, Andrews WL, Hall MS, et al. Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition[ J]. J Parenter Enteral Nutr, 1995,19(2) :114 - 118.
  • 7Carbonell-Estrany X, Figueras-Aloy J, Alvarez E. Erythro poietin and prematurity: where do we stand [ J ]. Perinat Med, 2005,33 (4) :277 - 286.
  • 8Surico G, Muggeo P, Muggeo V,et al. Parenteral iron sup- plementation for the treatment of iron deficiency anemia in children [ J ]. Ann Hemato1,2002,81 ( 1 ) : 154 - 157.
  • 9Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of re- combinant human erythropoietin in critically il1 patients: a randomized controlled trial [ J ]. JAMA, 2002, 288 (2) : 2827 - 2835.
  • 10Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients [J]. J Am Soc Nephrol, 2000, 11(3) :530 -538.

共引文献15

同被引文献39

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部